drugset / Trial / NCT00440466

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

NCT00440466

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with anemia associated with chronic kidney disease, is not less effective than treatment with epoetin alfa that is given once a week

Timeline

Start
2007-07
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 20000 iu Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 80000 iu Subcutaneous

Indications